Is Sinovac Biotech Ltd. (NASDAQ: SVA) living on borrowed time?


Here is a look at the scorecard of Sinovac Biotech Ltd. (NASDAQ:SVA) for the most recent quarter as well as analyst estimates for the coming periods.

The company generated sales of 28.74M%, implying an increase of 0.42%% compared to a similar quarter a year earlier. The revenue growth accelerated/decelerated by grow%.

To achieve the reported sales of 28.74M% for the quarter, the company incurred $5.71M in cost of goods. Therefore, after taking into account the cost of sales, Sinovac Biotech Ltd. emerged with a gross income of $23.03M.

Recently, Sinovac Biotech Ltd. (NASDAQ:SVA) announced that as a result of support from new investors and existing shareholders it had raised $1,500,000.

Let?s look into the technical of the stock

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.

Sinovac Biotech Ltd. also incurred other expenses in the course of operation. So after taking those into account as well, it exited the quarter with EPS of $0.06. The company had 57.02M diluted outstanding shares at the end of the quarter.

For the next quarter, analysts on the average are modeling EPS of $.

Sinovac Biotech Ltd.?s cash balance at the end of the most recent quarter was 54.63M%. The company generated free cash flow of $(4.8M) during the quarter, with net operating cash flow being $(1.19M). Net change in cash was $3.81M.

That said, Sinovac Biotech Ltd. finished the quarter with debt of 31.84M%. The debt increased/fell by growing from the past period.

What is Wall Street thinking about Sinovac Biotech Ltd.? To put the analyst recommendation into perspective, recommendation in the range of 1.00 – 1.24 implies a BUY recommendation, while 1.25 – 1.74 implies OVERWEIGHT. HOLD recommendation is represented by 1.75 – 2.24, UNDERWEIGHT is represented by 2.25 – 2.74 while SELL is represented by 2.75 – 3.00.

Does Sinovac Biotech Ltd. have a healthy balance sheet? A look at the company?s balance sheet at the end of the most recent quarter shows that it reflects total assets of $203.72M, offset by total liabilities of $72.76M.